217 related articles for article (PubMed ID: 27005283)
21. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.
Piccolo P; Lenci I; di Paolo D; Demelia L; Sorbello O; Nosotti L; Angelico M
Antivir Ther; 2013; 18(1):57-64. PubMed ID: 22872648
[TBL] [Abstract][Full Text] [Related]
22. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response.
Samiullah S; Bikharam D; Nasreen
World J Gastroenterol; 2012 Oct; 18(40):5793-8. PubMed ID: 23155322
[TBL] [Abstract][Full Text] [Related]
23. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response.
Tangkijvanich P; Chittmittraprap S; Poovorawan K; Limothai U; Khlaiphuengsin A; Chuaypen N; Wisedopas N; Poovorawan Y
J Viral Hepat; 2016 Jun; 23(6):427-38. PubMed ID: 26387494
[TBL] [Abstract][Full Text] [Related]
24. Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience.
Abbas Z; Memon MS; Mithani H; Jafri W; Hamid S
Antivir Ther; 2014; 19(5):463-8. PubMed ID: 24423484
[TBL] [Abstract][Full Text] [Related]
25. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).
Brouwer WP; Xie Q; Sonneveld MJ; Zhang N; Zhang Q; Tabak F; Streinu-Cercel A; Wang JY; Idilman R; Reesink HW; Diculescu M; Simon K; Voiculescu M; Akdogan M; Mazur W; Reijnders JG; Verhey E; Hansen BE; Janssen HL;
Hepatology; 2015 May; 61(5):1512-22. PubMed ID: 25348661
[TBL] [Abstract][Full Text] [Related]
26. Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.
Loglio A; Ferenci P; Uceda Renteria SC; Tham CYL; van Bömmel F; Borghi M; Holzmann H; Perbellini R; Trombetta E; Giovanelli S; Greco L; Porretti L; Prati D; Ceriotti F; Lunghi G; Bertoletti A; Lampertico P
J Hepatol; 2019 Oct; 71(4):834-839. PubMed ID: 31302176
[TBL] [Abstract][Full Text] [Related]
27. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
Luo XD; Chen XF; Zhou Y; Chen XP
J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
[TBL] [Abstract][Full Text] [Related]
28. Complete cure of HBV-HDV co-infection after 24weeks of combination therapy with pegylated interferon and ribavirin in a patient co-infected with HBV/HCV/HDV/HIV.
Gozlan J; Lacombe K; Gault E; Raguin G; Girard PM
J Hepatol; 2009 Feb; 50(2):432-4. PubMed ID: 19070927
[TBL] [Abstract][Full Text] [Related]
29. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
Gluhovschi C; Gadalean F; Kaycsa A; Curescu M; Sporea I; Gluhovschi G; Petrica L; Velciov S; Bozdog G; Bob F; Vernic C; Cioca D
Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):744-50. PubMed ID: 21320001
[TBL] [Abstract][Full Text] [Related]
30. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta.
Niro GA; Ciancio A; Gaeta GB; Smedile A; Marrone A; Olivero A; Stanzione M; David E; Brancaccio G; Fontana R; Perri F; Andriulli A; Rizzetto M
Hepatology; 2006 Sep; 44(3):713-20. PubMed ID: 16941685
[TBL] [Abstract][Full Text] [Related]
31. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir.
Sonneveld MJ; Zoutendijk R; Hansen BE; Janssen HL
Antivir Ther; 2012; 17(8):1605-8. PubMed ID: 22898565
[TBL] [Abstract][Full Text] [Related]
32. Interferon-α for patients with chronic hepatitis delta: a systematic review of randomized clinical trials.
Lamers MH; Kirgiz ÖÖ; Heidrich B; Wedemeyer H; Drenth JP
Antivir Ther; 2012; 17(6):1029-37. PubMed ID: 22892440
[TBL] [Abstract][Full Text] [Related]
33. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ
Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir.
Chen GY; Su TH; Kao JH
J Formos Med Assoc; 2015 Nov; 114(11):1140-1. PubMed ID: 23791143
[TBL] [Abstract][Full Text] [Related]
35. Dynamics of in vivo hepatitis D virus infection.
Goyal A; Murray JM
J Theor Biol; 2016 Jun; 398():9-19. PubMed ID: 27012516
[TBL] [Abstract][Full Text] [Related]
36. Entecavir treatment of chronic hepatitis D.
Kabaçam G; Onder FO; Yakut M; Seven G; Karatayli SC; Karatayli E; Savas B; Idilman R; Bozdayi AM; Yurdaydin C
Clin Infect Dis; 2012 Sep; 55(5):645-50. PubMed ID: 22573857
[TBL] [Abstract][Full Text] [Related]
37. HDV evolution-will viral resistance be an issue in HDV infection?
Tabernero D; Cortese MF; Buti M; Rodriguez-Frias F
Curr Opin Virol; 2018 Oct; 32():100-107. PubMed ID: 30415162
[TBL] [Abstract][Full Text] [Related]
38. Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.
Dinkelborg K; Kahlhöfer J; Dörge P; Yurdaydin C; Hardtke S; Caruntu FA; Curescu MG; Yalcin K; Akarca US; Gürel S; Zeuzem S; Erhardt A; Lüth S; Papatheodoridis GV; Keskin O; Port K; Radu M; Celen MK; Idilman R; Weber K; Stift J; Wittkop U; Heidrich B; Mederacke I; von der Leyen H; Dienes HP; Cornberg M; Koch A; Manns MP; Wedemeyer H; Deterding K;
Liver Int; 2023 Aug; 43(8):1663-1676. PubMed ID: 37183524
[TBL] [Abstract][Full Text] [Related]
39. Molecular epidemiology of hepatitis B and Delta virus strains that spread in the Mediterranean North East Coast of Tunisia.
Yacoubi L; Brichler S; Mansour W; Le Gal F; Hammami W; Sadraoui A; Ben Mami N; Msaddek A; Cheikh I; Triki H; Gordien E
J Clin Virol; 2015 Nov; 72():126-32. PubMed ID: 26513762
[TBL] [Abstract][Full Text] [Related]
40. Treatment of delta hepatitis.
Gunsar F
Expert Rev Anti Infect Ther; 2013 May; 11(5):489-98. PubMed ID: 23627855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]